| P2093 | author name string | Burke JM | |
| | O'Reilly RJ | |
| | Divgi CR | |
| | Larson SM | |
| | Sgouros G | |
| | Jurcic JG | |
| | Caron PC | |
| | Finn RD | |
| | Papadopoulos EB | |
| | Panageas KS | |
| | Scheinberg DA | |
| P2860 | cites work | Total body irradiation before allogeneic bone marrow transplantation: is more dose better? | Q32149186 |
| | Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation | Q34298262 |
| | Venoocclusive disease of the liver following bone marrow transplantation | Q39688572 |
| | Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity | Q40416428 |
| | Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first compl | Q43629955 |
| | Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study | Q43684700 |
| | Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies | Q43819615 |
| | Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia | Q44237334 |
| | A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide | Q44690521 |
| | Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide | Q52873579 |
| | The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia | Q67585402 |
| | A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression | Q68768839 |
| | Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias | Q70543529 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 549-556 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias | |
| P478 | volume | 32 | |